The first month of 2022 brought us some very encouraging developments on the CBD research front. Let’s get right into the CBD news highlights from January that are likely to be of most interest to you.
Study Finds That 2 Raw Hemp Compounds Can Block COVID-19
Researchers at Oregon State University published a study that made national news in January. They found that two compounds from the raw hemp plant (CBDA and CBGA) show the ability to prevent the virus that causes COVID-19 from entering human cells. By binding to the SARS-CoV-2 spike protein, they may block “a critical step in the process that the virus uses to infect people.”
More research is certainly needed before anyone should conclude that CBDA and CBGA can be effective at treating or preventing COVID-19. It should also be noted that most of the CBD products currently available to users don’t contain material levels of these raw cannabinoids.
New Study Shows No Evidence of Liver Toxicity From CBD
The question of whether CBD causes liver damage has been around for a few years. “CBD can cause liver injury” is currently listed as a potential harm on the U.S. Food & Drug Administration (FDA) website. In fact, a research study from 2019 did conclude that people who use CBD are at an “elevated risk for liver toxicity.”
However, a new study published in January 2022 calls that previous research and the FDA warning into question. The observational data from 839 participants found that “CBD at the doses consumed in the study is not associated with clinical liver toxicity. Our hope is that additional research can answer this question once and for all.
Increased Interest in CBD for Treating Skin Conditions
A recent study published in the Journal of Drugs in Dermatology found that 17.6% of those surveyed use an over-the-counter cannabis product to treat a skin condition. Most commonly, they used it to treat acne (28%) and psoriasis (26%).
The study concluded that consumers are very interested in using medical cannabis products for skin care, especially for inflammatory skin disorders. It also recommended more targeted education for dermatologists so they are more knowledgeable about these products.